These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15095297)

  • 41. H-2/myc, E mu/myc, and c-myc transgenic mice: potent sources of early hematopoietic cell lines.
    Roland J; Morello D
    Cell Growth Differ; 1993 Nov; 4(11):891-900. PubMed ID: 8297795
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Functional validation of genes implicated in lymphomagenesis: an in vivo selection assay using a Myc-induced B-cell tumor.
    Yu D; Cozma D; Park A; Thomas-Tikhonenko A
    Ann N Y Acad Sci; 2005 Nov; 1059():145-59. PubMed ID: 16382050
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lessons from Using Genetically Engineered Mouse Models of MYC-Induced Lymphoma.
    Winkler R; Piskor EM; Kosan C
    Cells; 2022 Dec; 12(1):. PubMed ID: 36611833
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MM-1, a c-Myc-binding protein, is a candidate for a tumor suppressor in leukemia/lymphoma and tongue cancer.
    Fujioka Y; Taira T; Maeda Y; Tanaka S; Nishihara H; Iguchi-Ariga SM; Nagashima K; Ariga H
    J Biol Chem; 2001 Nov; 276(48):45137-44. PubMed ID: 11567024
    [TBL] [Abstract][Full Text] [Related]  

  • 45. cDNA-library testing identifies transforming genes cooperating with c-myc in mouse pre-B cells.
    Wolf I; Bouquet C; Melchers F
    Eur J Immunol; 2016 Nov; 46(11):2555-2565. PubMed ID: 27538750
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Deregulated c-myc expression is insufficient for emergence of the tumorigenic phenotype in malignancy-suppressed intratypic T-cell lymphoma hybrids: an in vitro model for multistep lymphomagenesis.
    Kubota K; Tamauchi H; Nakazato K
    Cancer Lett; 1996 Mar; 101(2):199-203. PubMed ID: 8620470
    [TBL] [Abstract][Full Text] [Related]  

  • 47. TC-PTP is required for the maintenance of MYC-driven B-cell lymphomas.
    Young RM; Polsky A; Refaeli Y
    Blood; 2009 Dec; 114(24):5016-23. PubMed ID: 19755676
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recurrent chromosomal aberrations in INK4a/ARF defective primary lymphomas predict drug responses in vivo.
    Helmrich A; Lee S; O'Brien P; Dörken B; Lowe SW; Schröck E; Schmitt CA
    Oncogene; 2005 Jun; 24(26):4174-82. PubMed ID: 15824738
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MYC levels govern hematopoietic tumor type and latency in transgenic mice.
    Smith DP; Bath ML; Metcalf D; Harris AW; Cory S
    Blood; 2006 Jul; 108(2):653-61. PubMed ID: 16537801
    [TBL] [Abstract][Full Text] [Related]  

  • 50. c-Myc dependent initiation of genomic instability during neoplastic transformation.
    Taylor C; Jalava A; Mai S
    Curr Top Microbiol Immunol; 1997; 224():201-7. PubMed ID: 9308243
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Conditional transgenic models define how MYC initiates and maintains tumorigenesis.
    Arvanitis C; Felsher DW
    Semin Cancer Biol; 2006 Aug; 16(4):313-7. PubMed ID: 16935001
    [TBL] [Abstract][Full Text] [Related]  

  • 52. c-MYC-miRNA circuitry: a central regulator of aggressive B-cell malignancies.
    Tao J; Zhao X; Tao J
    Cell Cycle; 2014; 13(2):191-8. PubMed ID: 24394940
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction.
    Choi PS; van Riggelen J; Gentles AJ; Bachireddy P; Rakhra K; Adam SJ; Plevritis SK; Felsher DW
    Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17432-7. PubMed ID: 21969595
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reduction of Prep1 levels affects differentiation of normal and malignant B cells and accelerates Myc driven lymphomagenesis.
    Iotti G; Mejetta S; Modica L; Penkov D; Ponzoni M; Blasi F
    PLoS One; 2012; 7(10):e48353. PubMed ID: 23133585
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance.
    van Riggelen J; Müller J; Otto T; Beuger V; Yetil A; Choi PS; Kosan C; Möröy T; Felsher DW; Eilers M
    Genes Dev; 2010 Jun; 24(12):1281-94. PubMed ID: 20551174
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Deletion of the transcriptional regulator TFAP4 accelerates c-MYC-driven lymphomagenesis.
    Potts MA; Mizutani S; Garnham AL; Li Wai Suen CSN; Kueh AJ; Tai L; Pal M; Strasser A; Herold MJ
    Cell Death Differ; 2023 Jun; 30(6):1447-1456. PubMed ID: 36894688
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Generation of a Tetracycline Regulated Mouse Model of MYC-Induced T-Cell Acute Lymphoblastic Leukemia.
    Mahauad-Fernandez WD; Rakhra K; Felsher DW
    Methods Mol Biol; 2021; 2318():297-312. PubMed ID: 34019298
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Establishment and identification of bone morrow specific transgenic mouse model with tumorigenesis by mutant Myc retrovirus infection.].
    Guo CB; Jin XQ; Zhang MM; Pu CL; Li YC; Kang Q
    Zhonghua Xue Ye Xue Za Zhi; 2010 Apr; 31(4):236-9. PubMed ID: 20510039
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The ribonucleotide reductase R2 gene is a non-transcribed target of c-Myc-induced genomic instability.
    Kuschak TI; Taylor C; McMillan-Ward E; Israels S; Henderson DW; Mushinski JF; Wright JA; Mai S
    Gene; 1999 Oct; 238(2):351-65. PubMed ID: 10570963
    [TBL] [Abstract][Full Text] [Related]  

  • 60. c-MYC-induced genomic instability.
    Kuzyk A; Mai S
    Cold Spring Harb Perspect Med; 2014 Apr; 4(4):a014373. PubMed ID: 24692190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.